Research Analysts Issue Forecasts for biote Q1 Earnings

biote Corp. (NASDAQ:BTMD) – Analysts at B. Riley issued their Q1 2025 EPS estimates for shares of biote in a research note issued to investors on Thursday, March 13th. B. Riley analyst J. Van. Sinderen anticipates that the company will earn $0.04 per share for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q2 2025 earnings at $0.05 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $0.42 EPS and FY2027 earnings at $0.71 EPS.

Separately, Craig Hallum decreased their price target on biote from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday.

biote Price Performance

NASDAQ:BTMD opened at $3.76 on Monday. biote has a 1-year low of $3.04 and a 1-year high of $8.44. The firm has a 50-day moving average of $4.96 and a two-hundred day moving average of $5.55. The stock has a market cap of $204.31 million, a P/E ratio of 14.46 and a beta of 1.07.

Hedge Funds Weigh In On biote

A number of hedge funds have recently bought and sold shares of the company. Wasatch Advisors LP boosted its stake in biote by 8.4% in the third quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock valued at $7,772,000 after acquiring an additional 107,792 shares during the period. Dimensional Fund Advisors LP boosted its stake in biote by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company’s stock valued at $4,211,000 after acquiring an additional 3,065 shares during the period. State Street Corp boosted its stake in biote by 13.7% in the third quarter. State Street Corp now owns 475,491 shares of the company’s stock valued at $2,653,000 after acquiring an additional 57,290 shares during the period. Kanen Wealth Management LLC acquired a new position in shares of biote during the fourth quarter worth approximately $1,791,000. Finally, Northern Trust Corp boosted its position in shares of biote by 9.9% during the fourth quarter. Northern Trust Corp now owns 288,336 shares of the company’s stock worth $1,782,000 after buying an additional 25,873 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.